BioStem Technologies, Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
BioStem Technologies signed a Common Stock Purchase Agreement dated September 18, 2026, with Roth Principal Investments, LLC, establishing a $40 million equity commitment (or 19.99% of outstanding shares, whichever is lower). The investor will purchase shares at market prices through multiple daily mechanisms (pre-market, open, intraday, post-market), with a 10% commitment fee (capped at $400,000) withheld from purchase proceeds. BioStem immediately paid $75,000 in investor legal fees and $50,000 for qualified independent underwriter fees; the investor retains 4.99% beneficial ownership limits. A 36-month Investment Period applies post-commencement, subject to FINRA approval and SEC registration requirements.
Why this rating
At $48.8M total assets, a $40M commitment is material in size but structured as optional draws by company; $400K max fee is ~0.8% of assets. Real financing tool but non-dilutive until deployed; neutral absent execution.
Extracted items
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.